Real-World Patient Characteristics, Treatment Patterns, and Outcomes for Patients With Stage III or IV Classic Hodgkin Lymphoma Treated With Frontline ABVD: A Retrospective Database Review in the United States.

[1]  M. Fanale,et al.  Economic Burden of Hematopoietic Cell Transplantation (HCT) Among Commercially Insured Patients with Hematological Malignancies in the United States (US) , 2022, Blood.

[2]  R. Advani,et al.  Overall Survival with Brentuximab Vedotin in Stage III or IV Hodgkin's Lymphoma. , 2022, The New England journal of medicine.

[3]  R. Advani,et al.  NCCN Guidelines® Insights: Hodgkin Lymphoma, Version 2.2022. , 2022, Journal of the National Comprehensive Cancer Network : JNCCN.

[4]  R. Advani,et al.  Outcomes Among Classical Hodgkin Lymphoma Patients After an Interim PET Scan: A Real-World Experience. , 2021, Clinical lymphoma, myeloma & leukemia.

[5]  A. Evens,et al.  Classical Hodgkin Lymphoma; Real-World Observations from Physicians, Patients, and Caregivers on the Disease and Its Treatment (CONNECT): Observations of Physicians on Treatment and Interim PET-Adapted Regimens , 2021, Blood.

[6]  G. Frezza,et al.  Role of radiotherapy to bulky sites of advanced Hodgkin lymphoma treated with ABVD: final results of FIL HD0801 trial , 2021, Blood advances.

[7]  R. Greil,et al.  PET-guided eBEACOPP treatment of advanced-stage Hodgkin lymphoma (HD18): follow-up analysis of an international, open-label, randomised, phase 3 trial. , 2021, The Lancet. Haematology.

[8]  N. Robert,et al.  Real-World Adherence to National Comprehensive Cancer Network (NCCN) Guidelines Regarding the Usage of PET/CT and Reported Deauville Scores in Advanced Stage Classical Hodgkin Lymphoma: A Community Oncology Practice Perspective , 2020 .

[9]  J. Burke,et al.  Real-World Characteristics of Patients with Classical Hodgkin Lymphoma Receiving Frontline Brentuximab Vedotin with Chemotherapy: A Retrospective Analysis with Propensity Score Matching , 2020, Blood.

[10]  G. Salles,et al.  Resources-Stratified Guidelines for Classical Hodgkin Lymphoma , 2020, International journal of environmental research and public health.

[11]  M. Angelopoulou,et al.  Optimizing outcomes in relapsed/refractory Hodgkin lymphoma: a review of current and forthcoming therapeutic strategies , 2020, Therapeutic advances in hematology.

[12]  D. Klonoff.  The Expanding Role of Real-World Evidence Trials in Health Care Decision Making , 2020, Journal of diabetes science and technology.

[13]  Sonali M. Smith,et al.  Five-Year Follow-up of SWOG S0816: Limitations and Values of a PET-Adapted Approach for Stage III/IV Hodgkin Lymphoma. , 2019, Blood.

[14]  R. Bouabdallah,et al.  PET-adapted treatment for newly diagnosed advanced Hodgkin lymphoma (AHL2011): a randomised, multicentre, non-inferiority, phase 3 study. , 2019, The Lancet. Oncology.

[15]  G. Samsa,et al.  Patient-reported distress in Hodgkin lymphoma across the survivorship continuum , 2018, Supportive Care in Cancer.

[16]  J. Feliciano,et al.  Real-world analysis of cost, health care resource utilization, and supportive care in Hodgkin lymphoma patients with frontline failure , 2018, ClinicoEconomics and outcomes research : CEOR.

[17]  A. Rossi,et al.  Early Chemotherapy Intensification With Escalated BEACOPP in Patients With Advanced-Stage Hodgkin Lymphoma With a Positive Interim Positron Emission Tomography/Computed Tomography Scan After Two ABVD Cycles: Long-Term Results of the GITIL/FIL HD 0607 Trial. , 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[18]  R. Greil,et al.  PET-guided treatment in patients with advanced-stage Hodgkin's lymphoma (HD18): final results of an open-label, international, randomised phase 3 trial by the German Hodgkin Study Group , 2017, The Lancet.

[19]  J. Connors,et al.  Brentuximab Vedotin with Chemotherapy for Stage III or IV Hodgkin's Lymphoma , 2017, The New England journal of medicine.

[20]  Mimi Y. Kim,et al.  New methods for estimating follow-up rates in cohort studies , 2017, BMC Medical Research Methodology.

[21]  J. Radford,et al.  RESPONSE‐ADJUSTED THERAPY FOR ADVANCED HODGKIN LYMPHOMA (RATHL) TRIAL: LONGER FOLLOW UP CONFIRMS EFFICACY OF DE‐ESCALATION AFTER a NEGATIVE INTERIM PET SCAN (CRUK/07/033). , 2017 .

[22]  R. Gascoyne,et al.  Evaluation of the Risk of Relapse in Classical Hodgkin Lymphoma at Event-Free Survival Time Points and Survival Comparison With the General Population in British Columbia. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[23]  F. d'Amore,et al.  Adapted Treatment Guided by Interim PET-CT Scan in Advanced Hodgkin's Lymphoma. , 2016, The New England journal of medicine.

[24]  J. Armitage,et al.  Managing Risk in Hodgkin Lymphoma. , 2015, Clinical advances in hematology & oncology : H&O.

[25]  J. Friedberg,et al.  Treatment of Hodgkin lymphoma: a 50-year perspective. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[26]  V. Diehl,et al.  Treatment of Hodgkin lymphoma: the past, present, and future , 2008, Nature Clinical Practice Oncology.